Quick Answer
NEUROONE MEDICAL TECHNOLOGIES Corp reported Research And Development Expense of $4.98 million for the year ending 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed a decrease of -1.6% in Research And Development Expense from 2024 to 2025.
- This data is from NEUROONE MEDICAL TECHNOLOGIES Corp's annual report (Form 10-K), filed with the SEC on December 17, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $72.0 thousand | Q2 2017: $156.7 thousand | Q4 2017: $234.9 thousand | Q1 2018: $105.0 thousand | Q2 2018: $225.5 thousand | Q4 2018: $209.2 thousand | Q1 2019: $436.3 thousand | Q2 2019: $422.8 thousand | Q4 2019: $501.8 thousand | Q1 2020: $342.1 thousand | Q2 2020: $447.2 thousand | Q4 2020: $934.2 thousand | Q1 2021: $1.08 million | Q2 2021: $901.1 thousand | Q4 2021: $1.06 million | Q1 2022: $1.21 million | Q2 2022: $1.23 million | Q4 2022: $1.56 million | Q1 2023: $1.71 million | Q2 2023: $1.89 million | Q4 2023: $1.48 million | Q1 2024: $1.27 million | Q2 2024: $1.19 million | Q4 2024: $1.17 million | Q1 2025: $1.51 million | Q2 2025: $1.18 million | Q4 2025: $1.39 million.
- Over the full 7 years of available data (2019 to 2025), NEUROONE MEDICAL TECHNOLOGIES Corp's Research And Development Expense has grown by 225.9%.
- Historical annual values: Fiscal year 2025: $4.98 million | Fiscal year 2024: $5.07 million | Fiscal year 2023: $6.94 million | Fiscal year 2022: $4.93 million | Fiscal year 2021: $3.93 million | Fiscal year 2020: $2.08 million | Fiscal year 2019: $1.53 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: